NAD+ infusions: a much bigger spike, an infusion you have to sit through, and no outcome data

The expensive version of the NAD+ idea. It does produce concentrations the oral precursors cannot, and what that buys has never been measured against anything.

A different pharmacokinetic problem

Established clinical use Oral NMN and NR are precursors: they are absorbed and converted to NAD+ inside cells. Intravenous NAD+ delivers the coenzyme itself into the bloodstream, producing peak concentrations far above anything an oral dose reaches. That much is straightforward and is the whole rationale.

Animal-only or theoretical The complication is that NAD+ is a large, charged molecule that does not readily cross cell membranes, and what happens to an infused dose is contested. Much of it is degraded extracellularly to nicotinamide and other metabolites, which are then taken up and re-synthesised — in other words, the infusion may work substantially as an expensive precursor after all. Whether intracellular NAD+ in the tissues people care about rises more from an infusion than from a capsule is not established.

The infusion has to be given slowly for a reason that is itself informative. Pushed quickly it reliably causes chest tightness, flushing, nausea and a feeling of pressure — rate-dependent effects that are the standard experience rather than a rare reaction, which is why a session takes hours.

What has and has not been shown

Off-label or community practice The most substantive clinical use is in addiction and withdrawal, where NAD+ infusion protocols have been used for decades and studied in small trials with mixed results. There is also interest in neurodegenerative conditions and chronic fatigue. None of that amounts to an approval for anything, and the wellness use — energy, cognition, anti-ageing — has no controlled human evidence at all.

The oral comparison is the one worth making. Oral NMN and NR have placebo-controlled human trials demonstrating that blood NAD+ rises — a modest, verified biochemical effect. Intravenous NAD+ produces a much larger spike and has no comparable trial base for any outcome. Choosing the infusion is choosing a bigger biomarker change with less evidence behind it, at a hundred times the cost. The oral precursor page covers what that evidence actually says.

The practical shape of it

This is a clinic service rather than a compound someone doses at home: it needs intravenous access, hours of supervision, and it is expensive per session. The app’s own drawbacks list leads with exactly those, and it is the only entry in this reference where the delivery is the main constraint. This site names no clinic and no provider.

There is no monitoring marker. The app records general wellness self-assessment and liver enzymes for frequent high-dose infusions, which is honest — nothing on a routine panel reflects this, and specialty NAD+ assays are not standardised well enough to follow a trend against.

Animal-only or theoretical The same caution the oral page carries applies and applies more, since the concentrations are higher: NAD+ is required by proliferating cells, and anyone with a cancer history or under active surveillance has a reasonable question to put to an oncologist rather than to a clinic selling the infusion.

The dosing rows the app records

Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for NAD+ IV Protocol, verbatim. None of the analytes it names has a page here yet.

Drawbacks and risks the app records

From the app’s own entry, and it is unusually practical: the first three items are about the delivery rather than the molecule, which is a fair reflection of this one.

• Requires clinical setting and IV access
• Expensive per infusion ($300-1000 per session)
• Side effects during infusion: flushing, nausea, chest tightness (rate-dependent)
• Oral NMN/NR provides sustained levels vs spike
• Frequency for optimal benefit not established
• Insurance does not cover wellness NAD+ infusions

Questions people actually ask

Is an infusion better than oral NMN or NR?

It produces much higher blood concentrations. Whether that translates into more intracellular NAD+ where it matters is contested, and the oral precursors are the ones with placebo-controlled trials showing the biomarker moves. Bigger spike, less evidence.

Why does the infusion feel bad?

Chest tightness, flushing and nausea are rate-dependent and are the standard experience rather than a rare reaction. That is why a session is slow and takes hours.

Is it approved for anything?

No. It has been used in addiction and withdrawal protocols for decades with mixed small-trial results, and the wellness indications have no controlled human evidence.

Is there a test to see if it worked?

Not a usable one. Specialty NAD+ assays are not standardised well enough to follow a trend, and nothing on a standard panel reflects it.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.